This proposal describes a 5 - year training program for the development of an academic career in Laboratory Medicine. The PI has completed Residency training in Pathology and a Fellowship in Hemostasis Medicine at Emory University, and now proposes to expand his scientific skills through a unique integration of interdepartmental and inter-institutional resources that will promote a command of quantitative trait genetics and functional genomics as applied to thrombotic disease. Dr. Warren, an internationally recognized genetics investigator, will mentor the PI's scientific development. He is Chairmen of the Department of Genetics and has trained numerous postdoctoral fellows and graduate students. Dr. Lollar, Professor of Hematology, and Dr. John Blangero, Professor of Genetics will co-mentor the PI throughout this program. Dr. Lollar is a leading authority on f-IX structure/function while Dr. Blangero, the lead scientist of the GAIT Project, the only population-based family thrombosis study, and developer of the state-of-the-art statistical genetics software package SOLAR, both of which will be used in this research proposal. To enhance training the program enlists the expertise of Dr. T.J. Murphy, Professor of Pharmacology, land Dr. Stephanie Sherman, Professor of Genetics. Dr. Murphy developed the retroviral vectors that will be used in the analysis of f-IX gene expression. Dr Sherman, one of the top genetic epidemiologists in the country, has agreed to provide the PI with formal and informal training in statistical genetics and genetic epidemiology. In addition, an advisory committee of highly regarded medical scientists will provide scientific and career advice. The research will principally explore how f-IX genetic polymorphisms influence population variation in thrombosis risk by modulating f-IX expression levels and/or catalytic activity. We have identified most of the common f-IX polymorphisms and are the only lab in the U.S. with access to the genomic DNAs of the GAIT Project. Using an integrated experimental plan that incorporates molecular, biochemical, cellular and genetic approaches, the functional consequences of human f-IX genetic variation will be investigated and correlated with clinical parameters defined within the GAIT cohort. This will be the first comprehensive analysis of how such genetic variation impacts age-dependent and -independent thrombosis risk. By supporting such customized programs, which incorporate expertise from diverse resources at Emory and from outside institutions, the Pathology Department is an ideal setting for training physician-scientists and will provide an environment that enhances the PI's potential of developing into an independent investigator in thrombosis genetics.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-M (M1))
Program Officer
Mondoro, Traci
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
Schools of Medicine
United States
Zip Code
Sauna, Zuben E; Lozier, Jay N; Kasper, Carol K et al. (2015) The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics. Blood 125:223-8
Kim, Benjamin; Hing, Zachary A; Wu, Andrew et al. (2014) Single-nucleotide variations defining previously unreported ADAMTS13 haplotypes are associated with differential expression and activity of the VWF-cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family. Br J Haematol 165:154-8
Pandey, Gouri Shankar; Yanover, Chen; Howard, Tom E et al. (2013) Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment. PLoS Comput Biol 9:e1003066
Pandey, Gouri Shankar; Yanover, Chen; Miller-Jenkins, Lisa M et al. (2013) Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nat Med 19:1318-24
Pandey, Gouri Shankar; Tseng, Sandra C; Howard, Tom E et al. (2013) Detection of intracellular Factor VIII protein in peripheral blood mononuclear cells by flow cytometry. Biomed Res Int 2013:793502
Sauna, Z E; Ameri, A; Kim, B et al. (2012) Observations regarding the immunogenicity of BDD-rFVIII derived from a mechanistic personalized medicine perspective. J Thromb Haemost 10:1961-5
Howard, T E; Yanover, C; Mahlangu, J et al. (2011) Haemophilia management: time to get personal? Haemophilia 17:721-8
Viel, Kevin R; Ameri, Afshin; Abshire, Thomas C et al. (2009) Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 360:1618-27
Ameri, Afshin; Machiah, Deepa K; Tran, Thuy T et al. (2007) A nonstop mutation in the factor (F)X gene of a severely haemorrhagic patient with complete absence of coagulation FX. Thromb Haemost 98:1165-9
Viel, Kevin R; Machiah, Deepa K; Warren, Diane M et al. (2007) A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 109:3713-24

Showing the most recent 10 out of 11 publications